APSR2026-407

Yes
Late-Breaking
Submitted
Oral Presentation
AO16-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1220056-46903-Last _AO16-003_RSV_Vaccination_APSR_Revised_English 2_431234.pptx
Format: PPTX Only
 
Format: PDF Only
01. Clinical Respiratory Medicine
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Taichi Mochizuki * Mita Hospital International University of Health and Welfare, Tokyo, Japan Tokyo Japan
Naho Furusho - Mita Hospital International University of Health and Welfare Tokyo Japan
Ryuta Ueda - Mita Hospital International University of Health and Welfare Tokyo Japan
Kazuyoshi  Kuwano - Mita Hospital International University of Health and Welfare, Tokyo, Japan Tokyo Japan
Akira Umeda - Shioya Hospital International University of Health and Welfare Yaita-City Japan
Yasuo To - Narita Hospital International University of Health and Welfare, Tokyo, Japan Narita-City Japan
Seiichiro Sakao - Narita Hospital International University of Health and Welfare, Tokyo, Japan Narita-City Japan
 
 
 
 
 
 
 
 
Presenting Author Details
Taichi
Mochizuki
tmochister@gmail.com
+819057609498
61-70
Japan
Original Research
Current Status of RSV Vaccination at Our Hospital
Maximum 25 words
Abstract Content
Although RSV infections in adults are often mild, they can exacerbate underlying conditions such as bronchial asthma and COPD. Furthermore, chronic diseases associated with high hospitalization rates due to RSV infection are considered major components of multimorbidity. Among respiratory diseases, bronchial asthma and COPD are notable examples. In 2023, the U.S. FDA approved the first RSV vaccine. We evaluated the efficacy of RSV vaccination.
We examined exacerbations of underlying conditions during the one-year period before and after RSV vaccination.
We analyzed 146 individuals who received the RSV vaccine. The study demonstrated efficacy, with exacerbations of bronchial asthma decreasing from 34.2% to 13.7%, COPD from 31.4% to 17.1%, and ACO from 38.9% to 16.7% over the one-year period before and after vaccination. Furthermore, the incidence of exacerbations for other respiratory diseases also decreased from 25.0% to 10.0% during the one-year period before and after RSV vaccination, indicating the vaccine’s efficacy.
RSV vaccination may contribute to reducing the rate of exacerbations in underlying conditions such as bronchial asthma and COPD.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
RSV Vaccination
maximum 3 keywords and no abbreviations, separated by commas
No COI to disclose
177